Effect Of Different Doses Of Rosuvastatin With Ezetimibe On Blood Lipid Level And Inflammatory Factors In Patients With Coronary Heart Disease

Objective:By analyzing the effect of different doses of rosuvastatin combined with ezetimibe on blood lipid levels and inflammatory factors in patients with coronary heart disease,explores the effect of different doses of rosuvastatin combined with ezetimibe on the efficacy of coronary heart disease patients and the safety of using rosuvastatin,which provides a basis for coronary heart disease patients using rosuvastatin and ezetimibe.Methods:A total of 180 patients with coronary heart disease collected in our hospital from January 2017 to January 2019 were selected as the research objects,and randomly divided them into control group,observation group 1 and observation group2 according to different doses,containing 60 cases in each group.All three groups of patients were treated conventionally.The control group only used conventional treatment of coronary heart disease including ezetimibe without rosuvastatin calcium.Besides the conventional treatment,the observation group 1 was given rosuvastatin calcium at a dose of 10 mg / qn as well and the observation group 2 add a dose of rosuvastatin calcium 20 mg / qn during this period.The treatment effect and adverse reactions of the three groups of patients were compared after two weeks.Results:1.Comparison of blood lipid levels(1)The levels of TG,TC and LDL-C in the observation group 1 and the observation group 2 after the treatment were significantly lower than those in the control group(P <0.05);(2)The HDL-C level in the observation group 1 and the observation group 2after treatment was significantly higher than that of the control group,which shows a significant difference(P <0.05);(3)The levels of TG,TC and LDL-C in the observation group 2 after treatmentwere significantly lower than those in the observation group 1(P <0.05);(4)The HDL-C level of observation group 2 was significantly higher than that of observation group 1 after treatment,and the difference was significant(P <0.05).2.Comparison of serum inflammatory factors(1)The levels of Hs-CRP,TNF-α,IL-6 in the control group after treatment were higher than those in observation group 1 and observation group 2,and the difference was significant(P <0.05);(2)The Hs-CRP,TNF-α and IL-6 of the observation group 2 after treatment were lower than those of the observation group 1(P <0.05).3.Comparison of incidence of adverse reactionsThe incidence of adverse reactions such as nausea,diarrhea,vomiting,and myalgia,there was no significant difference between the three groups,and it was not statistically significant(P> 0.05).4.Comparison of overall efficacy(1)The treatment efficiency of observation group 1(86.7%)and the treatment efficiency of observation group 2(98.3%)were significantly higher than those in control group(81.7%),and the difference between the three groups was significant(P<0.05);(2)The treatment efficiency of observation group 2(98.3%)was significantly higher than that of observation group 1(86.7%),and the difference was significant(P<0.05).Conclusion:1.The use of ezetimibe and other conventional treatments for coronary heart disease combined with rosuvastatin tablets is more effective than only uses ezetimibe and other conventional treatments for coronary heart disease.2.Ezetimibe combined with rosuvastatin at a dose of 20 mg / qn was more effective than rosuvastatin combined with a dose of 10 mg / qn in reducing serum inflammatory factor levels and improving blood lipid levels in patients with coronary heart disease.3.The conventional treatment of coronary heart disease such as ezetimibe and the addition of rosuvastatin tablets are better than the traditional treatment of coronary heart disease such as ezetimibe in the treatment of coronary heart disease patients.4.Ezetimibe combined with rosuvastatin at a dose of 20 mg / qn is better than rosuvastatin combined with a dose of 10 mg / qn in patients with coronary heart disease.5.Compared with the combination of rosuvastatin at a dose of 20 mg / qn and the combination of rosuvastatin at a dose of 10 mg / qn,ezetimibe has no significant increase in adverse reactions in the near future,and it has good safety.